Aktis Oncology, Inc. (AKTS) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Aktis Oncology, Inc. (AKTS) posted $6.50M in revenue for fiscal 2025 (up 336.9% year over year), with a net loss of $63.73M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Aktis Oncology, Inc.
Aktis Oncology, Inc. has grown revenue from — to $6.50M over the last 4 fiscal years. The most recent year was up 336.9%.
Net margin sits at -980.9%, up 1976.7 points year over year.
It clears 1 of 4 deterministic health checks. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Aktis Oncology, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Aktis Oncology, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about AKTS — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Aktis Oncology, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | $1.49M | $6.50M |
| Gross profit | — | — | — | — |
| Net income | $-17.93M | $-28.64M | $-43.98M | $-63.73M |
| Net margin | — | — | -2957.6% | -980.9% |
Source: Aktis Oncology, Inc. SEC filings (10-K).
Aktis Oncology, Inc. financial health: 1 of 4 checks passed
- ✗Net margin above 10% (-980.9%)
- ✓More cash than total debt (cash 226.8M vs debt 0M)
- ✗Free cash flow positive (latest yr) (-73.7M)
- ✗Share count falling over 3 yrs (buybacks) (52.5M → 52.5M shares)
Checks computed deterministically from filed annual statements — no AI judgement.
Aktis Oncology, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -980.9%).
Explore 4 years of Aktis Oncology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track AKTS in your portfolio →
Aktis Oncology, Inc. financial history
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Aktis Oncology, Inc. — frequently asked questions
What is Aktis Oncology, Inc.'s revenue?
Aktis Oncology, Inc. (AKTS) reported revenue of $6.50M for fiscal year 2025, up 336.9% from the prior year, according to its SEC filings.
Is Aktis Oncology, Inc. profitable?
No — AKTS reported a net loss of $-63.73M in fiscal 2025.
What is Aktis Oncology, Inc.'s market cap?
Aktis Oncology, Inc. (AKTS) has a market capitalization of about $1.03B, based on the latest data in our nightly-refreshed cache.
When does Aktis Oncology, Inc.'s fiscal year end?
AKTS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Aktis Oncology, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.